ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acadia Pharma (ACAD) Misses Q2 EPS by 6c; Lowers Outook
August 8, 2018 4:07 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.51), $0.06 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $57.1 million versus the consensus estimate of $58.63 million.
GUIDANCE:
ACADIA is lowering its 2018 NUPLAZID net sales guidance to be between... More
